Cyrano Therapeutics has developed a unique, proprietary intranasal formulation to restore function in patients with a chronic loss of taste and smell. This is a condition affecting more than 40 million people in the US and Europe and millions more across the world, having a significant impact on safety, quality of life and well-being. Currently no marketed pharmaceutical therapy exists and aside from the Cyrano product, none are in the pipeline.
The Cyrano formulation (CYR-064) has been tested with success in a 92 patient pilot study and the Company is currently enrolling patients in a Phase 2 placebo-controlled double-blind randomized trial at 14 sites in the United States with data readout expected in Q1'25.
Additional information can be found on our website www.cyranotherapeutics.com
Company Details
- Employees
- 6
- Founded
- -
- Address
- 190 Congress Park Dr,
- he****@****ics.com
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- cyranotherapeutics.com
- Keywords
- Geneve.
- HQ
- Delray Beach, Florida
Cyrano Therapeutics Questions
Cyrano Therapeutics's website is cyranotherapeutics.com
Cyrano Therapeutics's LinkedIn profile is https://www.linkedin.com/company/cyrano-therapeutics
Cyrano Therapeutics has
6 employees.
View email and phone details for 6
employees at Cyrano Therapeutics.
Cyrano Therapeutics's industry is
Pharmaceutical Manufacturing
Cyrano Therapeutics's top competitors are
Orbital Therapeutics,
Neuroem,
The Smell & Taste Lab,
Verve Therapeutics,
Respira Therapeutics, Inc.,
Cyclo Therapeutics, Inc.,
The Bio Collective | Pending B Corp™,
Edgewise Therapeutics,
Dyne Therapeutics,
Tessera Therapeutics.
Cyrano Therapeutics's support email address is hello@cyranotherapeutics.com
Cyrano Therapeutics's categories are Pharmaceutical Manufacturing
Cyrano Therapeutics's founding year is 2014
